C-Kit point mutations in core binding factor leukemias: Correlation with white blood cell count and the white blood cell index [7]

Leukemia

Volumn 17, Issue 2, 2003, Pages 471-472

  Cairoli, R ^a   Grillo, G ^a   Beghini, A ^b   Tedeschi, A ^a   Ripamonti, C B ^b   Larizza, L ^b   Morra, E ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; STEM CELL FACTOR;

ADOLESCENT; ADULT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 16; CHROMOSOME ANALYSIS; CHROMOSOME INVERSION; CHROMOSOME TRANSLOCATION 21; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE DELETION; GENE INSERTION; HEMATOLOGICAL PARAMETERS; HUMAN; LETTER; LEUKAPHERESIS; LEUKEMIA; LEUKOCYTE COUNT; MALE; MUTATIONAL ANALYSIS; POINT MUTATION; PRIORITY JOURNAL; PROTO ONCOGENE; STEM CELL TRANSPLANTATION;

EID: 0037330478     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402795     Document Type: Letter

References (9)

1. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motojy T, Omoto E, Saito H, Ohno R, Ueda R. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
2. Schnittger S, Schoh C, Dugas M, Kern W, Staib P, Wuchter C, Loffler H, Sauerland CM, Serve H, Buchner T, Haferlach T, Hiddeman. Analysis of FLT3 length mutation in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
3. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, Wermke M, Bornhauser M, Ritter M, Neubauer A, Ehninger G, Illmer T. Analysis of FLT3-activating mutation in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of a sugroups with poor prognosis. Blood 2002; 99: 4326-4335.
4. Beghini A, Cairoli R, Morra E, Larizza L. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent c-kit mutation. Blood Cells Mol Dis 1998; 24: 262-270.
5. Beghini A, Larizza L, Cairoli R, Morra E. c-kit activating mutations and mast cell proliferation in human leukemia. Blood 1998; 92: 701-702.
6. Beghini A, Peterlongo P, Ripamonti CB, Larizza L, Cairoli R, Morr E, Mecucci C. C-kit mutations in core binding factor leukemias. Blood 2000; 95: 726-727.
7. Gari M, Goodeve A, Wilson G, Winship P, Langabeer S, Linch D, Vandeberghe E, Peake I, Reilly J. c-kit proto-oncogene exone 8 in-frame deletion plus insertion mutation in acute myeloid leukemia. Br J Haematol 1999; 105: 894-900.
8. Nguyen S, Leblanc T, Fenaux P, Witz F, Blaise D, Pigneux A, Thom X, Rigal-Huguet F, Lioure B, Auvrignon A, Fiere D, Reiffers J, Castaigne S, Leverger G, Harousseau JI, Socie G, Dombret H. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML intergroup. Blood 2002; 99: 3517-3523.
9. Schlenk RF, Dohner H, Pforsich M, Benner A, Fischer K, Hartmann F, Fischer JT, Weber W, Gunzer U, Pralle H, Has R. Successful collection of peripheral blood progenitor cells in patients with acute myeloid leukemia following early consolidation therapy with granulocyte colony-stimulating factor-supported high-dose cytarabine and mitoxantrone. Br J Haematol 1997; 99: 386-393.